Session 110
A Win for the World: The Johnson & Johnson/Merck COVID-19 Vaccine Collaboration

This session will be a 45-minute moderated discussion examining this lifesaving partnership between two great pharma companies, including the alliance's formation, challenges, victories, and lessons learned.

Explore this partnership's development through the eyes of key executives from each organization focusing on their culture, guiding principles, and the journey toward creating an agreement and on through the structure and process that allowed this highly impactful alliance to achieve the success of developing and supplying this vaccine. Hear how the governance process (formal and informal) was led and managed the collaboration with a high level of visibility and success. Understand the challenges that occur when two big pharma companies get together, demonstrating the amazing power of collaboration and the incredible success this partnership delivered during a global pandemic.

Key takeaways:


Michael Leonetti, CSAP
President & CEO
Association of Strategic Alliance Professionals




Leigh Cherry
Vice President, Strategic Business Support, Janssen Supply Chain
Janssen Pharmaceutical Companies of Johnson & Johnson

Leigh is the head of Janssen Supply Chain's Strategic Business Support organization leading the evaluation, negotiation, and execution of business development transactions on behalf of Janssen Supply Chain. Leigh is a leader within Janssen's Value Chain Management organization with responsibility for end-to-end supply chain oversight of products both commercial and in development.

With over 30 years of pharmaceutical supply chain experience, Leigh has held various roles leading manufacturing operations in biologics, vaccines, and small molecules, large molecule and medical device external manufacturing, value chain management, procurement, planning, business development, and alliance management. Leigh joined the Johnson & Johnson Family of Companies in 2016. Leigh previously worked at Merck & Co., Inc.

Leigh holds a Bachelor of Science degree in electrical engineering from Lafayette College and a Master of Business Administration from Harvard Business School.

John Glavas
Associate Vice President External Manufacturing and Strategy

John Glavas has over 25 years of operational experience in both Pharmaceutical and Biotechnology industries. John joined Merck as AVP Site Lead for Merck's Oss Biologics, Netherlands's manufacturing site in 2017 and as a member of the Global Biologics and Sterile Leadership Team. Currently John manages Merck's COVID response Program as part of the Merck Manufacturing Division.

Prior to joining Merck John was Vice-President and Site Director for GSK's Ste-Foy, Quebec vaccines manufacturing site from 2010 and was a member of the Canadian Country Management Board representing the Vaccines Manufacturing business. John oversaw and managed the manufacturing and supply of seasonal and pandemic influenza vaccine sourced from the Quebec site.

Prior to joining GSK, John worked as VP Manufacturing, Global Operations at PharmaScience Inc. He also held several roles at Draxis Pharma Inc. within Engineering, Production and finally as General Manager Non-Sterile Business Unit. During these 25 years in the pharmaceutical industry, he built a reputation as a strong leader with a proven track record in successfully delivering large scale, trans formative, projects for the businesses.

John has a bachelor's degree in chemical engineering and a master's degree in manufacturing management from McGill University.